AstraZeneca PLC (AZN) Stock: Price, Forecast & Analyst Target
AstraZeneca PLC (AZN) — MoonshotScore 85/100 (Exceptional band), calculated Nov 18, 2026. Price $178.76 (-1.93%), as of the Nov 18, 2026 trading session; market cap $277B. Expected results Feb 9, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 33.98× (cash as of Sep 30, 2026) · expected results Feb 9, 2027
AstraZeneca PLC · AZN · NYSE · Healthcare · Drug Manufacturers - General
Research dated 2026-09-12: AstraZeneca discovers, develops, manufactures and commercializes prescription medicines, with oncology, cardiovascular, renal, metabolic and rare-disease franchises carrying the business today. Its case depends on whether expanding medicine sales can keep outrunning heavy pipeline spending while preserving cash generation and containing leverage.
Price as of Nov 18, 2026
Key Statistics
MoonshotScore v2 · AstraZeneca (AZN)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Elite quality and durable growth, but a full valuation; the market is already moving on it. Business Quality: Elite; Financial Safety: Okay; Valuation: Full; Growth Durability: Compounding; Momentum: Surging.
- EPS beat 6 of the last 8 reports
- Altman Z 3.59 · Piotroski F 7
- ROE 22.3% · ROA 9.3% · current ratio 1.01 · earnings yield 3.9% · free-cash-flow yield 3.2%
Helping: business quality, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 87 | Exceptional | |
| 88 | Exceptional | |
| 87 | Exceptional | |
| 87 | Exceptional | |
| 85 | Exceptional | |
| 85 | Exceptional |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $178.76 | |
| Change on the day | -1.93% | |
| 52-week range | $153.41–$212.71 | |
| Market capitalisation | $277B | — |
| Price / earnings (trailing) | 25.58 | |
| Shares traded on the day | 2.54M | |
| Beta (volatility vs the S&P 500) | 0.21 | |
| Dividends per share (last 12 months) | $3.23 | |
| Dividend yield (last 12 months) | 1.77% |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings call · management outlook
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Management outlook
R&D represented 23% of total revenue in the first 9 months, and we continue to expect it to be at the upper end of the low 20s percentage range for the full year.
Aradhana Sarin · Statement from
As we indicated previously, we expect gross margin in the second half to be below the first half, reflecting the seasonal demand profile of lower-margin medicines such as FluMist and Beyfortus.
Aradhana Sarin · Statement from
How to read these dates
A statement's date is the earnings call where it was made, not a deadline. Management expectations and estimated dates can change.
Other perspectives
Council score for AstraZeneca (AZN): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
5 lenses, 5 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
One of these lenses reads this company less favourably than the MoonshotScore does: Englander-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is AstraZeneca (AZN), and what does it report?
Short answer · as of
AstraZeneca is an integrated global biopharmaceutical company, not a development-stage biotech awaiting a flagship approval. It sells established prescription medicines through primary and specialty care channels while funding discovery, clinical development, manufacturing and commercialization across a broad geographic network.
Research dated 2026-09-12.
The reporting mixes therapeutic-area totals with named medicine sales: oncology and rare disease appear alongside Tagrisso and Farxiga, while cardiovascular, renal and metabolic medicine revenue is also grouped as a franchise. Those lines describe the portfolio from different angles and should not be treated as mutually exclusive components.
What do the latest results show for AstraZeneca (AZN)?
Research dated 2026-09-12.
Revenue edged higher in the latest reported period, and gross profit also advanced, but operating profit, net income and earnings per share retreated as research and commercial spending rose. Reported earnings exceeded expectations while revenue came in slightly below expectations, breaking the recent run of revenue outperformance without erasing the broader annual growth trend.
Management reiterated its constant-currency growth outlook and continues to direct an elevated share of revenue toward research spanning oncology technologies and the cardiovascular, renal and metabolic pipeline. It also expects product mix to pressure gross margin as seasonal demand shifts toward lower-margin FluMist and Beyfortus, making the revenue mix as important as the revenue direction.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $15.99B Sep 30, 2026
- Latest quarter · R&D
- $3.60B Sep 30, 2026
- Latest quarter · SG&A
- $5.26B Sep 30, 2026
- Latest quarter · FMP standardized operating result
- $4.32B Sep 30, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | $15.99B | $3.60B | $5.26B | $4.32B |
| Jun 30, 2026 | $15.38B | $4.05B | $5.80B | $3.16B |
| Mar 31, 2026 | $15.29B | $3.49B | $5.06B | $4.25B |
| Dec 31, 2025 | $15.50B | $3.86B | $5.64B | $2.98B |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $16.21B Oct 30, 2026
- Latest report · revenue estimate
- $16.00B Oct 30, 2026
- Latest report · revenue vs estimate
- Above estimate Oct 30, 2026
- Latest report · EPS vs estimate
- Above estimate Oct 30, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Oct 30, 2026 | $16.21B | $16.00B | $2.7900 | $2.6000 |
| Jul 27, 2026 | $15.38B | $15.44B | $2.6300 | $2.5000 |
| Apr 29, 2026 | $15.29B | $14.93B | $2.5800 | $2.5700 |
| Feb 10, 2026 | $15.50B | $15.44B | $2.1200 | $2.0900 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2025 | $15.19B | $2.53B | $1.62 (diluted) |
| Q4 FY2025 | $15.50B | $2.33B | $1.48 (diluted) |
| Q1 FY2026 | $15.29B | $3.08B | $1.97 (diluted) |
| Q2 FY2026 | $15.38B | $2.51B | $1.59 (diluted) |
What are the financial strengths and risks for AstraZeneca (AZN)?
Short answer
Cash and short-term investments were $8.15B at the Sep 30, 2026 balance-sheet date. Operating cash flow was $4.66B for the quarter ended Sep 30, 2026, meaning operations generated cash. These figures do not establish a cash runway.
Research dated 2026-09-12.
Operating cash flow has remained positive throughout the displayed history despite substantial capital expenditure and rising research investment. Profitability screens remain healthy, but the latest cash balance declined from the preceding period and near-term liquidity ratios indicate that liquid current resources do not fully cover current obligations.
Debt materially exceeds cash and short-term investments, and it remains larger even when long-term investment holdings are included. AstraZeneca therefore needs its marketed portfolio to keep funding pipeline investment and capital needs; weaker sales from major franchises, heavier commercialization expense or the expected unfavorable product mix would reduce the room available for debt service and reinvestment.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- $4.66B Sep 30, 2026
- Previous quarter · operating cash flow
- $2.89B Jun 30, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Sep 30, 2026 | $4.66B | −$666.87M |
| Jun 30, 2026 | $2.89B | −$752.85M |
| Mar 31, 2026 | $3.36B | −$1.54B |
| Dec 31, 2025 | $2.43B | −$1.05B |
How to read these figures
Amounts are in US dollars. Negative operating cash flow means the business used cash. Capital spending is shown as reported; we do not combine it into a free-cash-flow or runway estimate. The bars share one scale.
What should you watch next at AstraZeneca (AZN)?
Short answer · as of
The next earnings report is expected on Feb 9, 2027.
Research dated 2026-09-12.
The upcoming report should be read through product mix rather than revenue alone. Watch whether overall sales maintain momentum, whether earnings growth holds as research and commercial costs rise, and whether the anticipated FluMist and Beyfortus mix change produces the gross-margin pressure management described.
Cash conversion is the financial cross-check: operating cash flow should remain sufficient after capital spending while cash, investments and debt stay in balance. Tagrisso, Farxiga, the broader oncology franchise and rare disease sales deserve particular attention because their scale makes them central to whether commercial growth can absorb sustained pipeline investment.
What management is planning
Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.
As in prior years, we expect a sequential step-up in the fourth quarter versus third quarter in operating expenses.
Aradhana Sarin ·
We expect the other operating income in the second half of the year to be slightly higher than the first half.
Aradhana Sarin ·
How does AstraZeneca compare with its peers?
Short answer
AstraZeneca's score ranks tied for 3rd of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-12.
AstraZeneca combines the commercial reach of a global drug manufacturer with research spending more commonly associated with an aggressively expanding pipeline. Unlike a biotech whose value rests mainly on future approvals, AstraZeneca already draws substantial sales from oncology, cardiovascular, renal, metabolic and rare-disease medicines while developing new modalities through internal work and collaborations.
Oncology is the largest disclosed therapeutic grouping, but the business is not an oncology pure play: Farxiga, the wider cardiovascular, renal and metabolic franchise, and rare disease provide meaningful commercial breadth. That mix spreads demand across established medicines and treatment areas, while retaining exposure to the research cost and execution risk inherent in bringing new therapies to market.
| Company | Price | Market value | Score |
|---|---|---|---|
| $1382.75 Nov 18, 2026 | $1.23T | 98 5-pillar Nov 18, 2026 | |
| $47.12 Nov 18, 2026 | $113B | 87 5-pillar Nov 18, 2026 | |
| AstraZeneca (AZN) — this page | $178.76 | $277B | 85 |
| $59.56 Nov 18, 2026 | $122B | 85 5-pillar Nov 18, 2026 | |
| $443.89 Nov 18, 2026 | $240B | 84 5-pillar Nov 18, 2026 | |
| $272.70 Nov 18, 2026 | $656B | 83 5-pillar Nov 18, 2026 | |
| $286.01 Nov 18, 2026 | $506B | 83 5-pillar Nov 18, 2026 | |
| $155.21 Nov 18, 2026 | $293B | 82 5-pillar Nov 18, 2026 | |
| $48.58 Nov 18, 2026 | $97.4B | 77 5-pillar Nov 18, 2026 | |
| $168.98 Nov 18, 2026 | $210B | 72 5-pillar Nov 18, 2026 | |
| $137.78 Nov 18, 2026 | $340B | 69 5-pillar Nov 18, 2026 | |
| $28.06 Nov 18, 2026 | $160B | 67 5-pillar Nov 18, 2026 | |
| $8.47 Nov 18, 2026 | $5.76B | 60 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $206.00 – $216.00
- Consensus target
- $211.00
- Median target
- $211.00
Consensus record · Captured .
Measured against a quoted price of $178.76 (as of Nov 18, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 6, 2026
- Transactions
- 7
- Identified insiders
- 1
- Purchases
- 1
- Sales
- 0
- Other transactions
- 6
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Institutional ownership
- 51.0% Period end Sep 30, 2026
- Previous quarter · ownership
- 52.0% Prior to period end Sep 30, 2026
- Reporting holders
- 1,478 Period end Sep 30, 2026
- Previous quarter · holders
- 1,529 Prior to period end Sep 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Investor Ab | 51,587,810 |
| Vanguard Capital Management LLC | 45,656,840 |
| Capital World Investors | 31,088,437 |
| Wellington Management Group Llp | 30,837,503 |
| Fmr LLC | 29,383,096 |
Tracked investors
Which of the 16 named investors we follow held AZN in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported AZN in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Sep 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about AstraZeneca (AZN)?
AstraZeneca Healthcare Stock: Key Questions Answered
Research dated 2026-09-12; the full attribution is under Sources. The last 3 questions are answered from this page's own dated data, not from the research.
How do Tagrisso and Farxiga fit into AstraZeneca’s reported revenue?
Tagrisso and Farxiga are named medicine sales presented alongside broader therapeutic-area totals. Adding every displayed line together would overstate revenue because the presentation describes overlapping portfolio views rather than independent segments.
Why can AstraZeneca’s gross margin weaken while revenue grows?
Management expects seasonal demand for lower-margin FluMist and Beyfortus to weigh on product mix. Revenue can therefore advance while the profit retained from each unit of sales declines.
Can AstraZeneca fund its pipeline from operating cash flow?
Operating cash flow has stayed positive across the displayed periods while research spending remained elevated, although capital expenditure absorbs a meaningful portion. The durability of that funding model depends on marketed medicines continuing to support pipeline and infrastructure investment.
Is AstraZeneca mainly an oncology company?
Oncology is its largest disclosed therapeutic grouping, led in part by Tagrisso, but AstraZeneca also has substantial cardiovascular, renal, metabolic and rare-disease businesses. Farxiga and the rare-disease portfolio make the company broader than an oncology pure play.
What is the AZN stock price today?
The last price recorded for AstraZeneca PLC (AZN), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the AZN price target?
The analyst consensus price target for AstraZeneca PLC (AZN), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Does AZN pay a dividend?
Yes. The dividend yield of AstraZeneca PLC (AZN) over the last 12 months, with its date, is listed under Price & valuation on this page. Payout ratio and cash-flow coverage decide whether it can last, and past dividends do not guarantee future payments.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 83 figures on this page — 2 from SEC filings and earnings calls, 71 from Financial Modeling Prep (FMP), 4 with no recorded source, 5 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources (as of 2026-09-12), by section of the research
ETFs that hold AZN
Funds in our ETF coverage that list AZN among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| Thornburg International Equity ETF (TXUE) | 3.36% |